TCT 699: Preclinical evaluation of a thin-strut biodegradable stent in a porcine coronary artery restenosis model
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Merill Lifesciences
- Consultant Fee/Honoraria/Speaker's Bureau - Novartis; SMT; AstraZenca
- Equity/Stock(s)/Options - Innovation for Heart and Vessels